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Abstract
Background: Stroke is one of the most prevalent neurological diseases in the United States. Community-acquired
pneumonia (CAP) is the leading cause of infections in survivors of stroke. There is limited research evaluating the clinical outcomes of CAP in patients with stroke. The objective
of this study was to evaluate the clinical characteristics and
outcomes of hospitalized patients with CAP and a history of
stroke.
Methods: This was a secondary analysis of the University
of Louisville Pneumonia Study database. Patients were divided into two groups based on the presence or absence of
a history of stroke. Clinical outcomes were length of stay,
time to clinical stability, and one-year mortality, which were
assessed via stratified Cox proportional hazards regression.

Introduction
Stroke is the fifth leading cause of death in the United
States.[1] Its prevalence is approximately 3% in adults,
affecting approximately 7 million individuals nationwide.[2] It is among the ten leading causes of chronic
disability.[3, 4] Surviving patients experience a wide
range of complications that may require subsequent
hospital admissions. The most frequent causes of readmission to the hospital within five years of the initial stroke are recurrent stroke, infection, and cardiac
events.[5] Cerebral ischemia and damage to the central
nervous system can significantly increase a patient’s
susceptibility to systemic infections.[6]
Researchers have studied various infections in patients
during the acute phase of stroke, among which pneumonia remains the most common cause of infectionrelated short-term and long-term hospital readmission.[5, 7-9] General functional decline and dysphagia after stroke put patients at significant risk of seULJRI | https://ir.library.louisville.edu/jri/vol6/iss1/4

Differences in risk of clinical outcomes were reported as adjusted hazard ratios.
Results: We found no significant differences in time to clinical stability between the two groups. The median length of
stay for patients with a history of stroke hospitalized with CAP
was six days and for patients without stroke was five days
(P=0.01). We observed a 16% higher risk of mortality in
stroke patients with CAP than in the non-stroke population
(P=0.001).
Conclusions: This study indicates that hospitalized patients
with CAP have a longer hospital stay and higher mortality than
those without stroke.

vere lung infection.[10] Patients may present with nonspecific signs and symptoms of community-acquired
pneumonia (CAP), such as altered mental status due
to an impaired cough reflex. Furthermore, antiplatelet
and anti-inflammatory drug therapy can mask pyrexia
and acute inflammatory markers.[11] Katzan et al. observed a three-fold higher 30-day mortality rate in
patients who experienced pneumonia after an acute
stoke.[12]
Researchers have extensively studied the risk factors and clinical outcomes of aspiration- and strokeassociated pneumonia. However, there are few studies that investigate the clinical outcomes of CAP in patients with a history of stroke. The aim of our study
was to assess the clinical characteristics, incidence, and
outcomes of CAP in patients with a history of stroke.
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Methods
Study design and study population
This was a secondary analysis of the University of
Louisville Pneumonia Study database, which was a
prospective, observational cohort study of adult patients hospitalized with CAP in the city of Louisville,
Kentucky, from June 1, 2014, to May 31, 2016, and
from October 1, 2016, to March 31, 2017.[13] Data from
all hospitalized patients with CAP in Louisville from
the nine adult hospitals were reviewed and included
in the database. Institutional Review Board approval
was obtained (IRB number: 11.0613). The study was
exempt from informed consent. Data operations were
conducted by the study coordinating center located at
the University Of Louisville Division Of Infectious Diseases.
Inclusion criteria
The inclusion criteria have been described previously.[13] The diagnosis of CAP required the presence
of three criteria: (1) new pulmonary infiltrate on imaging (computed tomography [CT] scan or chest X-ray)
at the time of hospital admission; (2) the presence of at
least one of the following signs and symptoms of CAP:
new or increased cough, fever >100 °F or hypothermia
96 °F, leukocytosis >11,000 cells/mm3 , left shift >10%
band forms/mL, or leukopenia <4,000 cells/mL; and
(3) no alternative diagnosis at the time of hospital discharge to explain the first two criteria.
The term “stroke” referred to a medical history of
ischemic stroke, hemorrhagic stroke, or transient ischemic attack (TIA) as documented in medical records
or imaging. Patients were categorized into one of two
groups. The stroke group consisted of patients with
CAP and a documented history of stroke. The nonstroke group consisted of patients with CAP but without a documented history of stroke.
Study variables
We collected demographics, vital signs (temperature,
blood pressure, heart rate, and respiratory rate), laboratory tests on admission, and comorbidities. The following comorbidities were reviewed: neoplastic disease,
congestive heart failure (CHF), renal disease, liver disease, diabetes mellitus, chronic obstructive pulmonary
disease (COPD), coronary artery disease, essential arterial hypertension, hyperlipidemia, obesity, and current
smoking status.
Study outcomes
Time to clinical stability was evaluated daily within the
first seven days of hospitalization to determine the day
on which patients reached clinical stability. A patient
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was considered clinically stable when the following
four criteria were met: (1) improved cough and shortness of breath, (2) lack of fever for at least 8 hours, (3)
improving leukocytosis (decreased at least 10% from
the previous day), and (4) tolerating oral intake. Length
of stay (LOS) was defined as the number of days between admission and discharge. Patients hospitalized
for more than 14 days were censored at 14 days to capture LOS data related only to bacterial CAP. Mortality
was defined as death by any cause at any time within
one year of the day of hospitalization. Verification of
death was obtained from the Kentucky Department of
Vital Statistics.
Statistical analysis
Descriptive statistics were reported. Categorical data
were summarized as frequencies and percentages, and
continuous data were summarized as medians and interquartile ranges (IQR) or means and standard deviations (SD). Chi-squared tests of independence were
performed to test baseline descriptive statistics between groups for categorical data. Mann-Whitney U
tests were performed to test between groups for continuous data. Clinical outcomes were assessed via stratified Cox proportional hazards regression, adjusting
for CURB-65 score, age of 65 years or more, sex, race,
and histories of chronic obstructive pulmonary disease,
chronic heart failure, coronary artery disease, hypertension, and diabetes. Kaplan–Meier curves were produced. Differences in risk of clinical outcomes were reported as adjusted hazard ratios (aHR).

Results
During our study period, there were 10,101 adults hospitalized with CAP. Among them, 1,337 had a history
of stroke. Clinical characteristics and laboratory values for the two groups are described in Table 1. The
patients in the stroke group were older than those in
non-stroke group (71.32±14.47 vs. 65.87±16.79 years;
P<0.001) and more frequently had a medical history
of CHF, renal disease, diabetes, coronary artery disease with or without a myocardial infarction, hyperlipidemia, or hypertension; P<0.001 for each. Stroke
patients also more frequently had a family history of
coronary artery disease or a prior coronary intervention (percutaneous transluminal coronary angioplasty
or coronary artery bypass grafting [PTCA/CABG]);
P<0.001 for each. A greater proportion of patients in
the stroke group had altered mental status or suspicion
of aspiration at the time of admission; P<0.001. They
were also more frequently nursing home residents or
hospitalized for a period of more than two days within
the 90 days prior to admission for CAP. A greater proportion of patients in the stroke group were taking aspirin, statins, or antiplatelet drugs as home medications
prior to hospital admission; P<0.001 for each. The me-
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Table 1. Clinical characteristics of the study population, including demographics, social and medical history, indicators of severity of disease,
vital signs, and laboratory values at the time of admission.

Stroke∗
(n=1,337)

Non-stroke∗
(n=8,764)

P

71.32±14.47
609 (46)
269 (20)
322 (24)

65.87±16.79
4064 (46)
1677 (19)
950 (11)

<0.001
0.595
0.416
<0.001

1126 (84)
809 (61)
538 (40)
551 (41)
573 (43)
293 (22)
322 (24)
404 (30)
632 (47)
473 (35)
322 (24)
415 (31)
161 (14)
80 (6)
504 (38)
4.26±1.90
872 (65)

5928 (68)
3684 (42)
2448 (28)
2756 (31)
2527 (29)
1043 (12)
1401 (16)
2214 (25)
4229 (48)
2391 (27)
2821 (32)
3101 (35)
1083(14)
633 (7)
2426 (28)
3.62±1.94
4413 (50)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.521
<0.001
<0.001
0.002
>0.999
0.112
<0.001
<0.001
<0.001

Severity
PSI, median [IQR]
Altered mental status
Ventilatory support
Vasopressors
Suspicion of aspiration

122 [98, 146]
365 (27)
181 (14)
44 (3)
247 (19)

98 [72, 127]
1486 (17)
1190 (14)
250 (3)
939 (11)

<0.001
<0.001
0.996
0.424
<0.001

Vitals, mean±SD
Temperature (°C)
Respiratory rate (breaths/minute)
Systolic blood Pressure (mmHg)
Diastolic blood pressure (mmHg)
Heart Rate (beats/minute)

37.37±0.88
24.20±7.00
118.45±27.98
56.90±16.53
102.92±23.78

37.41±0.96
24.30±7.07
117.87±26.56
59.42±17.19
106.20±22.63

0.15
0.639
0.463
<0.001
<0.001

Laboratory values, mean±SD
Hematocrit
Blood urea nitrogen (mg/dL)
Serum glucose (mg/dL)
Serum sodium (mEq/L)
Serum potassium (mEq/L)
Bicarbonate (mEq/L)
pH
Hemoglobin (g/dL)
White blood cell count×1,000/µL
Cholesterol (mg/dL)
Triglycerides (mg/dL)

34.67±6.12
27.71±19.47
179.10±99.86
137.87±5.67
4.10±0.73
25.65±5.77
7.39±0.08
11.20±2.09
13.36±7.59
135.46±47.23
119.44±75.04

35.62±6.39
23.53±17.36
170.41±91.41
138.27±122.99
4.09±2.24
26.33±7.23
7.38±0.10
11.65±3.04
13.36±7.65
139.73±45.48
121.15±119.80

<0.001
<0.001
0.001
0.905
0.872
0.033
0.039
<0.001
0.974
0.094
0.785

650 (49)
202 (15)
705 (53)

2879 (33)
532 (6)
2937 (34)

<0.001
<0.001
<0.001

Demographics
Age, mean±SD
Male
Black
Nursing home resident
Social and medical history
Essential arterial hypertension
Hyperlipidemia
Congestive heart failure
Diabetes
Coronary artery disease
Prior myocardial infarction
Prior PTCA/CABG
Family history of coronary artery disease
Chronic obstructive pulmonary disease
Renal disease
Current smoker
Obesity (BMI>30)
Neoplastic disease
Liver disease
Hospitalized >2 days in the prior 90 days
Number of comorbidities, mean±SD
≥4 comorbid conditions

Medications
Aspirin
Antiplatelet
Statins

Abbreviations: BMI, body mass index; IQR, interquartile range; PSI, Pneumonia Severity
Index; PTCA/CABG, percutaneous transluminal coronary angioplasty/coronary artery bypass graft; SD, standard deviation.
∗ n (%) except where otherwise specified.
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Figure 1. Kaplan–Meier curves for time to clinical stability for study population. Abbreviations: CVD+, stroke; CVD-, non-stroke.

dian Pneumonia Severity Index score was 122 in the
stroke population versus 98 in the non-stroke population; P<0.001. Diastolic blood pressure and heart rate
within the first 24 hours after admission were significantly lower in the stroke population; P<0.001 for each.
Temperature, respiratory rate, and systolic blood pressure during the same period were not significantly different between groups. We observed no significant differences in cholesterol and triglyceride levels between
the two groups. There was no significant difference in
the proportion of men or African American persons between the groups. A higher proportion of patients in
the non-stroke group smoked (32% vs. 24%; P<0.001)
or were obese (35% vs. 31%; P<0.001) than in the stroke
group.

3, 8). The Kaplan–Meier curve for length of stay can
be seen in Figure 2. After adjustment for confounding variables, we found significant differences in length
of stay (aHR for discharge 0.92 [95% CI 0.86–0.98];
P=0.01).

Time to clinical stability

This study demonstrated that adults hospitalized for
CAP with a history of stroke had longer hospital stays
and higher mortality within one year than those admitted for CAP without a history of stroke. Time to clinical
stability, another short-term outcome of the study, was
not significantly different between groups. The differences in length of stay and mortality were present after
adjusting for age and common comorbidities.

The median time to clinical stability for patients in both
groups was 2 days (stroke IQR 1, 4; non-stroke IQR 1,
3; Figure 1). After adjusting for confounding variables,
no significant differences were detected in time to clinical stability between the two groups (aHR for attaining
stability 0.94 [95% confidence interval (CI) 0.88–1.00];
P=0.084).
Length of stay
The median LOS for the stroke group was 6 days (IQR
4, 9). For the non-stroke group, LOS was 5 days (IQR
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Mortality
The patients with a history of stroke had a 16% higher
risk of death compared to the non-stroke population by
the end of one year (Figure 3). The observed aHR for
death was 1.16 (95% CI 1.04–1.29); P=0.001.

Discussion

It is possible that pathophysiological processes played
a role in the increased mortality and length of stay in
the stroke population admitted with CAP. One pathophysiological mechanism that could have contributed
to these differences is immune dysregulation following
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Figure 2. Kaplan–Meier curves for length of stay for study population.

severe brain injury associated with stroke.[14] Offner
et al. identified a series of events in post-stroke experimental animal models that can lead to the loss of
peripheral immune competence.[15] Additionally, they
observed reduced T cell activation and profound loss of
immune T and B cells in the spleen and thymus.[15] In
another study, all experimental mice developed spontaneous septicemia and pneumonia after three days of
focal cerebral ischemia.[16] Part of this immune depression serves as a protective mechanism to counteract the
effects of blood-brain barrier disruption and limit further tissue destruction.[6] Thus, brain inflammation following stroke can cause systemic immunosuppression,
resulting in increased susceptibility to infection.[15, 17]
Further research is needed to understand immune dysregulation and its clinical significance.

stroke, thus contributing to increased mortality. Additionally, patients with a history of stroke may be more
deconditioned and require more physical therapy after
an infection, particularly one serious enough to necessitate hospitalization; this may also contribute to delayed
discharge. Other factors, such as stroke-facilitated aspiration and general functional decline, can increase
risk of infection as well as severity of disease.[6, 10]
Krabbe et al. found that a chronic state of systemic inflammation and immune senescence in older patients
can contribute to increased susceptibility to infection
and worse clinical outcomes.[19] We observed that a
higher proportion of patients with stroke who were admitted for CAP had mental status changes and suspicion of aspiration than those admitted for CAP without
a history of stroke.

A recent study by Bordon et al. documented a statistically significant association between need for hospitalization and mortality in patients with CAP independent of comorbidities.[18] It was hypothesized that
CAP can cause an acute increase in cytokine expression. This acute systemic inflammation may destabilize atherosclerotic plaques and trigger events. CAP
can also produce a chronic inflammatory response. A
persistent, chronic inflammation would accelerate the
natural history of disease, explaining decreased patient
survival after CAP.

A systematic review found that over the last two
decades, several studies were conducted to examine the role of prophylactic antibiotics after an acute
stroke.[20] Multiple randomized controlled trials tested
the administration of different antibiotics, including
minocycline, moxifloxacin, levofloxacin, ceftriaxone,
and mezlocillin plus sulbactam, in stroke patients.
Meta-analysis of a portion of these studies, involving 506 patients, concluded that prophylactic antibiotic therapy contributed to a decrease in the incidence
of infection in patients with acute stroke compared to
patients on a placebo (22% vs. 36%; relative risk [RR]
0.58 [95% CI 0.43–0.79]). However, the rate of mortality was not significantly different between the two

Increased length of stay can increase the probability of
hospital-acquired infections in those who have had a
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Figure 3. Survival graph for the study population.

groups (13% vs. 15%; RR 0.85 [95% CI 0.47–1.51]).[20,
21] The growing burden of antimicrobial resistance
should be considered when treating individual patients
with prophylactic antibiotics. Researchers also studied immunotherapeutic and immune-stimulatory approaches to counteract immune depression after stroke
in animals.[16, 21] Scientists have tested the administration of T cells, natural killer cells, interferon-gamma
and beta-blockers in mouse models. However, the
clinical relevance of these studies is yet to be determined.[16, 21] Thus, future studies, including randomized controlled trials, are warranted to assess pharmacological and non-pharmacological approaches, such
as oral care, head elevation, swallowing rehabilitation,
and vaccination against pneumonia among stroke patients to prevent CAP. Clinicians also recommend postdischarge stratification of mortality risk that may help
to identify patients at greater risk of CAP.
We identified a few weaknesses for our study. Clinical
characteristic data were dependent on the accuracy of
the electronic medical records. The duration between
the occurrences of stroke and the onset of CAP was
not assessed; thus, the documented stroke may have
occurred at any time in the patient’s medical history.
Also, which patients had serious sequelae and which
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did not is not clarified in the study. Some patients may
have recovered almost completely years after a stroke
while recent stroke patients with serious sequelae may
have much greater predisposition to developing CAP.
Another limitation is that TIA patients were included,
but they actually may be at equivalent risk to a nonstroke patient if their cardiovascular risk factors were
corrected.
Our study had several strengths. At least three factors gave the present study increased generalizability:
the population varied in age, including adults above
18 years, with a large sample size; the study population was broadly representative, with 46% identifying
as men and 20% identifying as black; and the study
evaluated all adult patients hospitalized for CAP with
a previous history of stroke in Louisville during the
study period. Other strengths were that patients were
identified using social security numbers rather than the
medical record numbers and that CAP was defined using clinical criteria rather than billing information.
In conclusion, patients hospitalized for CAP with a history of stroke are likely to experience longer lengths of
stay and higher mortality than those without a history
of stroke.
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